These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 16648504

  • 1. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
    Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G.
    J Clin Oncol; 2006 May 01; 24(13):2044-51. PubMed ID: 16648504
    [Abstract] [Full Text] [Related]

  • 2. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J, Georgoulias V.
    Clin Lung Cancer; 2005 Nov 01; 7(3):183-9. PubMed ID: 16354313
    [Abstract] [Full Text] [Related]

  • 3. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, Ross G, Preston A, Lymboura M, Mattson K.
    Lung Cancer; 2005 Aug 01; 49(2):253-61. PubMed ID: 16022920
    [Abstract] [Full Text] [Related]

  • 4. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.
    Cancer; 2002 Oct 01; 95(7):1511-9. PubMed ID: 12237920
    [Abstract] [Full Text] [Related]

  • 5. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G.
    J Clin Oncol; 2007 May 20; 25(15):2086-92. PubMed ID: 17513814
    [Abstract] [Full Text] [Related]

  • 6. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
    Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlakou G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, Mavroudis D, Georgoulias V.
    Anticancer Res; 2010 Jul 20; 30(7):3031-8. PubMed ID: 20683051
    [Abstract] [Full Text] [Related]

  • 7. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F, Derin D, Guney N, Camlica H, Aydiner A, Topuz E.
    Lung Cancer; 2007 Jul 20; 57(1):79-83. PubMed ID: 17383768
    [Abstract] [Full Text] [Related]

  • 8. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL, Marks RS, Mahoney MR, Sloan JA, Bauman MD, Tazelaar HD, Kugler JW, Mailliard JA, Ebbert LP, Wiesenfeld M.
    Am J Clin Oncol; 2003 Jun 20; 26(3):236-40. PubMed ID: 12796591
    [Abstract] [Full Text] [Related]

  • 9. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
    Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C.
    Lung Cancer; 2005 Jun 20; 48(3):409-13. PubMed ID: 15893010
    [Abstract] [Full Text] [Related]

  • 10. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 11. [Cisplatin etoposide versus cisplatin/etoposide/ifosfamide combination chemotherapy in small-cell lung cancer: a multicenter randomized controlled study. Hokkaido Study Group of Treatment for Small-Cell Lung Cancer].
    Miyamoto H, Kawakami Y, Arimoto T, Asakawa M, Suzuki A, Fujikane T, Onodera S, Nakabayashi T, Yasuda S, Shimizu T.
    Gan To Kagaku Ryoho; 1991 Jun 15; 18(7):1127-34. PubMed ID: 1647149
    [Abstract] [Full Text] [Related]

  • 12. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
    O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T.
    J Clin Oncol; 2006 Dec 01; 24(34):5441-7. PubMed ID: 17135646
    [Abstract] [Full Text] [Related]

  • 13. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K, Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group.
    Clin Cancer Res; 2003 Jan 01; 9(1):143-50. PubMed ID: 12538462
    [Abstract] [Full Text] [Related]

  • 14. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 Jan 01; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, Spigel DR, Joseph G, Corso SW, Spremulli E, Hainsworth JD.
    Oncologist; 2005 Oct 01; 10(9):728-33. PubMed ID: 16249353
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS.
    Clin Cancer Res; 2003 Jun 01; 9(6):2085-91. PubMed ID: 12796372
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA, Al Omari A, Murry DJ, Case D.
    Lung Cancer; 2006 Dec 01; 54(3):379-85. PubMed ID: 17049403
    [Abstract] [Full Text] [Related]

  • 18. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T, Fukuoka M, Negoro S, Sugiura T, Kawahara M, Kudoh S, Araki J, Nakagawa K, Yokozaki M, Yamakido M, Ariyoshi Y.
    Gan To Kagaku Ryoho; 2000 Jul 01; 27(8):1091-6. PubMed ID: 10945001
    [Abstract] [Full Text] [Related]

  • 19. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M, Ochi Y, Kadota A, Akusawa H, Kisohara A, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 2000 Jul 01; 7(2):305-10. PubMed ID: 10671676
    [Abstract] [Full Text] [Related]

  • 20. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
    Sorensen M, Lassen U, Palshof T, Jensen BB, Johansen J, Jensen PB, Langer SW.
    Lung Cancer; 2008 May 01; 60(2):252-8. PubMed ID: 18036701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.